TransMedics Group (NASDAQ:TMDX) Sets New 1-Year High at $132.96

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as $132.96 and last traded at $130.10, with a volume of 49462 shares. The stock had previously closed at $132.65.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. TD Cowen upped their price target on TransMedics Group from $100.00 to $130.00 and gave the stock a "buy" rating in a report on Wednesday, May 1st. Piper Sandler reaffirmed an "overweight" rating and issued a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a report on Wednesday, May 1st. Morgan Stanley upped their price target on TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 28th. Canaccord Genuity Group increased their target price on TransMedics Group from $102.00 to $117.00 and gave the company a "buy" rating in a report on Wednesday, May 1st. Finally, Oppenheimer increased their target price on TransMedics Group from $105.00 to $125.00 and gave the company an "outperform" rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $119.00.

TransMedics Group Stock Down 4.0 %

The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. The business has a 50-day moving average price of $87.41 and a 200-day moving average price of $78.57. The firm has a market capitalization of $4.19 billion, a PE ratio of -374.35 and a beta of 1.87.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business's revenue was up 132.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.08) earnings per share. Equities research analysts forecast that TransMedics Group, Inc. will post 0.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 4,000 shares of the company's stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,047,155.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 12,000 shares of the company's stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares in the company, valued at $7,044,932.83. The disclosure for this sale can be found here. Over the last three months, insiders sold 241,246 shares of company stock worth $24,518,953. Company insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TMDX. Vanguard Group Inc. raised its stake in shares of TransMedics Group by 1.7% in the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company's stock valued at $99,341,000 after acquiring an additional 29,798 shares in the last quarter. Moody Aldrich Partners LLC raised its stake in shares of TransMedics Group by 110.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company's stock valued at $3,655,000 after acquiring an additional 24,290 shares in the last quarter. American Century Companies Inc. raised its stake in shares of TransMedics Group by 271.2% in the third quarter. American Century Companies Inc. now owns 486,956 shares of the company's stock valued at $26,661,000 after acquiring an additional 355,755 shares in the last quarter. Eagle Health Investments LP raised its stake in shares of TransMedics Group by 78.5% in the third quarter. Eagle Health Investments LP now owns 414,205 shares of the company's stock valued at $22,678,000 after acquiring an additional 182,173 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in shares of TransMedics Group by 31.2% in the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company's stock valued at $4,624,000 after acquiring an additional 20,081 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.